

Supplementary Table 2. Sample characteristics from clinical cohort. Diagnosis, disease status, and age are denoted at time of sample collection. Cells, reads per cell, valid reads, and percent of reads in cells extracted from Tapestry's analytical pipeline on BlueBee. All samples selected are normal karyotype with the exception of four complex karyotype samples (denoted with asterisk). Serial samples from the same patient are listed subsequently in the table and denoted with carrot.

Sample	Diagnosis	Disease Status	Age at sample collection (years)	Cells	Reads per cell	Valid reads	Percent of reads in cells
MSK1	AML	Relapse/Refractory	76.3	270	156141	1.4E+08	85.25
MSK2^	AML	Relapse/Refractory	76.3	217	164536	8.1E+07	63.9
MSK3	AML	Refractory	69.68	1352	65374.5	9E+07	76.51
MSK4		CH	47.2	9074	7042.5	6.4E+07	69.83
MSK5	sAML (MPN)	Newly Transformed	72.75	6433	18238.3	6.2E+07	79.03
MSK6	tAML	Newly Diagnosed	40.09	2273	20220	9.5E+07	86.96
MSK7	AML	MRD NEG CR	76.87	369	164931	7.2E+07	45.6
MSK8	AML	Relapsed	70.17	11337	5194.66	3.2E+07	53.34
MSK9	AML	Refractory	79.73	6904	15935.8	7.9E+07	85.52
MSK10	PMF	Persistent	74.47	1977	38781.4	2E+07	28.94
MSK11		CH	73.8	14937	6624.4	9.9E+07	55.45
MSK12	ET	Chronic Stage	53.04	2281	23374.8	1.1E+08	69.98
MSK13^	MF	Chronic Stage	54.81	2813	77030	6.9E+07	67.49
MSK14^	sAML (MF)	Blastic Phase	55.73	3260	34475	1.2E+08	84.81
MSK15		CH	67.6	13125	8031.2	1.1E+08	66.94
MSK16	sAML (CMML)	Newly Transformed	82.15	1334	53950.1	6.3E+07	76.58
MSK17	sAML	Newly Transformed	59.18	19237	4911.5	4E+07	66.83
MSK18		CH	69.7	22317	17881.8	4E+08	50.49
MSK19		CH	77.61	6813	10308	1.7E+08	62.26
MSK20	PV	Chronic Stage	72.53	5119	20537.7	1.7E+08	69
MSK21^	sAML	Blastic Phase	75.37	1513	25514	1.7E+08	87.15
MSK22^	Post-PV MF	Chronic Stage	74.73	8475	4132.11	4.2E+07	47.63
MSK23		CH	81.32	9909	7210.24	1.6E+08	70.41
MSK24	tAML	MRD+ CR	53.5	11296	8677.8	9.8E+07	70
MSK25^	tAML	Relapsed	53.6	3167	22732.5	7.2E+07	64.66
MSK26	MPN-NOS	Chronic Stage	77.79	7861	8386.39	5.8E+07	86.1

MSK27^	MF	Accelerated Stage	82.78	4806	20481.7	1.3E+08	86.01
MSK28	AML	Relapsed	58.19	15120	4175.57	8.5E+07	76.75
MSK29		CH	64.18	326	97263.1	2.8E+07	66.66
MSK30		CH	69.9	13164	6982.3	9.2E+07	68.92
MSK31		CH	64.4	10743	5391.12	1.3E+08	81.87
MSK32	AML	Refractory	74.78	669	94734.2	1.1E+08	87.55
MSK33		CH	84.79	1027	82183.6	8.4E+07	55.99
MSK34	AML	Newly Diagnosed	77.68	11087	7670	1.4E+08	88.52
MSK35	AML	Refractory	42.9	1157	41713.9	4E+07	60.93
MSK36	AML	Relapse/Refractory	67.32	10324	30926.8	3.6E+07	40.83
MSK37	CMML w/MF	Persistent	59.77	2693	32642.5	8.8E+07	80.58
MSK38	AML	Relapse	48.32	3198	15301.3	287649	28.96
MSK39	MF	Chronic Stage	53.46	3826	14082	7.3E+08	82.39
MSK40	sAML	Newly Transformed	56.8	7201	5331.2	5.4E+07	71.13
MSK41	AML	Newly Diagnosed	55.52	1367	46036.7	6E+07	83.3
MSK42	AML	Relapse/Refractory	50.1	2819	33317.9	5.1E+07	69
MSK43	MF	Chronic Stage	72.98	6044	10955.7	5.7E+07	62.85
MSK44^	sAML	Refractory	76.65	10063	4880.19	8.4E+07	68.02
MSK45	AML	Refractory	81.53	1089	35118.9	6.2E+07	76.07
MSK46	AML	Persistent (7% BM)	81.62	728	86986.7	4.9E+07	67.47
MSK47	AML	Relapsed	74.89	1610	58845.2	1.2E+08	78.55
MSK48		CH	64.13	2794	34013	9.5E+07	84.29
MSK49	sAML (Prior PV)	Relapse/Refractory	68.8	9366	8919.88	3.9E+08	80.87
MSK50	AML	Relapsed	65.16	14531	3120.03	4.9E+07	72.09
MSK51	sAML (Prev PV)	Relapsed	63.95	981	102507	9.1E+07	70.36
MSK52	AML	Refractory	68	3212	25891.5	8.7E+07	83.6
MSK53	sAML (Prev MDS)	Relapsed	78.99	848	46319.4	3.9E+07	77.14
MSK54^	sAML (Prev MDS)	Relapsed	78.99	2078	66166.2	6.2E+07	76.67
MSK55	AML	Relapse/Refractory	71.53	335	218026	4.1E+08	14.62
MSK56	MF	Chronic Stage	72.97	933	166876	7.8E+07	59.17
MSK57^	AML	Refractory	74.75	8465	3659.69	3.1E+07	75.01
MSK58		CH	75.35	11735	10098.7	9.9E+07	77.95
MSK59	MF	Chronic Stage	68.71	1242	68903.9	6.4E+07	56.06
MSK60	MF	Chronic Stage	61.98	2419	50010.8	7.5E+07	82.24

MSK61^	MF	Accelerated Stage	62.24	396	176986	6.7E+07	80.44
MSK62^	sAML	Newly Transformed	62.56	490	148847	3.8E+07	83.85
MSK63	AML	Relapse/Refractory	53.01	1411	44068.1	2.9E+07	74.07
MSK64	AML	Early Relapse post SCT	64.4	1252	44208.2	7.2E+07	68.1
MSK65	tAML	Newly Diagnosed	64.44	7134	10485.4	8.4E+07	83.09
MSK66*	AML	Refractory	67.95	7814	10757.4	8.8E+07	71.6
MSK67	AML	Refractory	72.72	15889	22898.1	7.3E+07	81.38
MSK68		CH	82.2	8243	7066.74	3.4E+07	68.41
MSK69	AML	Refractory	75.24	7173	15460.1	9.8E+07	85.05
MSK70^	AML	Refractory	75.47	856	80739.8	5.5E+07	76.18
MSK71^	AML	Refractory	75.55	12878	3027.41	7.7E+07	72.41
MSK72	sAML	Refractory	57.24	3195	42404	4.6E+07	26.17
MSK73	AML	Refractory	61.52	1302	64170.5	5.4E+07	74.01
MSK74		CH	62.1	2098	13857.8	2.9E+07	15.44
MSK75	Post-ET MF	Chronic Stage	64.61	4240	14061	7.6E+07	79.95
MSK76^	sAML	Newly Transformed	65.33	7033	13495.7	1.6E+08	57.56
MSK77*	AML	Refractory	70.96	9555	6371.68	3.3E+07	77.99
MSK78	AML	Relapsed	64.75	1830	48950.3	1E+08	76.23
MSK79	AML	Refractory	54.48	1709	78365.9	1.3E+08	72.31
MSK80^	AML	Refractory	54.48	1659	23813.9	9.5E+07	77.55
MSK81	AML	Relapsed	69.81	517	146075	5.8E+07	75.19
MSK82^	AML	MRD NEG CR	69.2	3833	15700.9	6E+07	76.32
MSK83^	AML	Persistent (7% PB)	70.2	10839	8849	9.6E+07	75.11
MSK84	AML	Newly Diagnosed	76.71	409	148324	3.9E+07	73.67
MSK85	sAML	Newly Transformed	79.85	391	52386.4	4.3E+07	53.5
MSK86	AML	Persistent Disease (7% BM)	78.26	12298	5998.35	9.3E+07	84.93
MSK87	AML	Relapsed	71.19	79	3641.13	6.3E+07	74.31
MSK88	sAML (MDS)	Newly Transformed	55.99	1805	41600.1	7.6E+07	72.04
MSK89	tAML	Newly Diagnosed	5.75	1069	67006.5	5.3E+07	80.8
MSK90	AML	Refractory	64.45	12188	6473.65	1E+08	79.94
MSK91	AML	Refractory	83.39	13052	3940.41	4.5E+07	65.98
MSK92	AML	Newly Diagnosed	24.3	1390	35513.1	1.1E+08	78.33

MSK93	AML	Newly Diagnosed	44.85	1113	25637.7	8.6E+07	65.46
MSK94	AML	Newly Diagnosed	66.29	910	27045.5	3.5E+07	65.89
MSK95	AML	Refractory	66.1	5179	16123.1	1.2E+08	80.95
MSK96^	sAML	Newly Transformed	65.7	14433	26014.2	3.8E+08	84.38
MSK97	AML	Refractory	81.73	1325	38813.6	5E+07	65.24
MSK98*	AML	Relapsed	70.93	11954	5665.72	7.1E+07	69.01
MSK99	AML	Refractory	68.97	5020	14391.9	4.1E+07	70.98
MSK100	AML	Refractory	69.17	8,580	69770.4	7.9E+07	74.34
MSK101	AML	Relapsed	61.64	331	236867	5.8E+07	68.72
MSK102^	AML	Relapse/Refractory	61.78	1277	132340	6.3E+07	79.9
MSK103^	AML	Relapse/Refractory	62.02	12680	6365.25	3.5E+08	21.46
MSK104	AML	MRD+ CR	63.3	9070	10754.5	7.7E+07	84.39
MSK105*	sAML	Newly Transformed	76.55	8943	10549.3	3.1E+07	75.01
MSK106	AML	Newly Diagnosed	71.7	3752	20588.8	4.9E+07	36.23
MSK107	AML	Relapse/Refractory	62.75	8367	13369.9	3.9E+07	74.78
MSK108^	AML	Persistent	62.85	220	310240	3.8E+07	60.4
MSK109	AML	Relapsed	59.39	6996	13984.3	7E+07	66.08
MSK110	AML	Relapsed	76.8	326	232188	4.7E+07	53.93
MSK111		CH	72.5	10168	5087.4	5.2E+07	59.15
MSK112	AML	Relapse	72.8	12976	4800.67	5.1E+07	61.85
MSK113	AML	Relapsed	86.96	8791	8121.92	7.1E+07	69.4
MSK114	AML	MRD NEG CR	45.39	189	245914	4.6E+07	76.26
MSK115	AML	Newly Diagnosed	59.37	616	93339.2	1.1E+08	68.54
MSK116	MDS	Persistent	60.11	252	223229	7.3E+07	65.32
MSK117	AML	Persistent	58.09	282	145254	6.1E+07	59.06
MSK118	MDS-MLD	Persistent	71.46	5848	15901.8	7.6E+07	72.55
MSK119	AML	Relapse	76.94	441	112395	5.6E+07	64.53
MSK120	AML	Refractory	68.52	321	194304	9.8E+07	81.09
MSK121	AML	Newly Diagnosed	75.79	6406	11796.1	7E+07	78.8
MSK122		CH	53.27	1268	37413.8	1.7E+08	83
MSK123	AML	Relapsed	71.84	990	54714.6	8.1E+07	80.89
MSK124		CH	73.93	12623	6448.22	6.2E+07	74.11
MSK125	CMML	Persistent	76.23	7114	8724.71	4.8E+07	66.32
MSK126	AML	Refractory	66.64	10354	8497.08	8.3E+07	73.21
MSK127	AML	Relapse/Refractory	37.68	1480	22450.5	9.4E+07	65.78
MSK128^	AML	Relapse/Refractory	37.68	7210	10323.4	7.4E+07	87.3

MSK129	AML	Newly Diagnosed	20.61	3518	18155.1	2.2E+08	84.46
MSK130^	AML	Newly Diagnosed	20.61	4363	22553.1	9.8E+07	57.87
MSK131	sAML (CMML to AMML)	Newly Transformed	69.95	657	27581.1	5.9E+07	68.54
MSK132	Post-ET MF	Persistent	78.4	4586	12703.6	7.1E+07	79.39
MSK133		CH	79.74	9852	7204	7.4E+07	72.44
MSK134	AML	Primary Refractory	33.95	4492	13410.9	1.8E+07	69.36
MSK135^	AML	Relapsed	33.9	12973	5225.7	6.8E+07	73.8
MSK136^	AML	Persistent AML (~20% BM)	35.1	2430	18828.1	4.6E+07	60.62
MSK137	AML	Refractory	77.6	9259	9370.12	9.4E+07	74.21
MSK138	sAML (CMML to AMML)	Newly Transformed	50.37	835	51223.3	6E+07	80.69
MSK139^	sAML (CMML to AMML)	Newly Transformed	50.37	2598	63597.6	1.7E+08	85.71
MSK140^	sAML	Newly Transformed	50.3	8332	7331.6	6.1E+07	69.56
MSK141^	sAML	Relapsed post SCT	50.8	8892	6972.1	6.2E+07	68.99
MSK142		CH	73.06	8990	9548.03	1.1E+08	81.35
MSK143		CH	73.82	7482	13562.8	8.1E+07	87.55
MSK144	AML	Newly Diagnosed	65.03	4693	16865.2	1.2E+08	80.24
MSK145	AML	Newly Diagnosed	70.84	7490	13255	6.6E+07	80.01
MSK146	AML	Newly Diagnosed	32.84	970	41029.5	7.3E+07	64.24
MSK147	AML	Newly Diagnosed	72.24	2527	28720.1	6.6E+07	77.46
MSK148		CH	79.9	11379	7964.88	6.9E+07	74.62
TJU17-003	AML	Newly Diagnosed	67	13092	6216.16	9.8E+07	85.39
TJU17-005	AML	Newly Diagnosed	66	8995	7637.22	8.4E+07	85.23
TJU17-006	AML	Newly Diagnosed	69	922	180336	6.1E+07	84.34
TJU17-020	AML	Newly Diagnosed	76	5887	26711.3	6.8E+07	80.31
TJU17-021^	AML	Newly Diagnosed	76	976	34475.9	9.4E+07	84.12
TJU18-003	AML	Newly Diagnosed	64	3918	7198.06	8.4E+07	86.3
UP3326	AML	Newly Diagnosed	71.1	1385	53475.2	1.1E+08	82.99
UP4410	AML	Relapsed	66.3	10766	12157.2	8.6E+07	77.85
UP5046	AML	Relapsed	70.6	10070	17158.9	2.5E+07	23.48
UP5346	AML	Newly Diagnosed	75.2	6651	16083.5	6.8E+07	59.56
UP5480	AML	Newly Diagnosed	68.4	10451	16149.9	7.2E+07	65.76
UP5522	tAML	Relapsed	74.9	7202	16460.1	5.8E+08	62.74
UP5941	AML	Newly Diagnosed	70.3	8426	7953.98	6.3E+07	66.68

UP6225	AML	Relapsed	68.1	6477	20632.8	7.4E+07	81.54
--------	-----	----------	------	------	---------	---------	-------